Atriva Therapeutics GmbH

Atriva Therapeutics mission is to develop an antiviral therapy platform against severe respiratory and systemic diseases with a high unmet medical need induced by RNA viruses, e.g., influenza and COVID-19. The clinical-stage biopharmaceutical company is pioneering the development of host-targeting antiviral therapies, making development of viral resistance unlikely, and thereby significantly contributing to pandemic preparedness. The Atriva lead product zapnometinib (ATR-002) is a first-in-class, host-targeting agent that aims to inhibit viral replication and to favorably modulate the bodys immune response to RNA viruses. Atriva Therapeutics was founded in 2015 in Tubingen by a team of leading scientists in viral research...

Biotechnology,antivirals,mek inhibitors,influenza,respiratory infection,viral infection,science,and innovation

Atriva therapeutics gmbh operates in the Biotechnology research industry.

Atriva therapeutics gmbh's revenue is 1m - 10m

Atriva therapeutics gmbh has 11 - 50 employees.